It has recently been reported that high concentrations of bromhexine, an expectorant and inhibitor of TMPRSS2 currently used in clinical trials against COVID-19 [78,79], unlike another expectorant, ambroxol, may favor the formation of syncytia [80]. This evidence concerns the gene TMPRSS2 and COVID-19.